Phaseline

Companies › Travere Therapeutics

Travere Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 7 registered trials: 3 Phase 2, 2 Phase 3, 1 Phase 4, 1 Phase 1; Cardiovascular, Genitourinary, Metabolic and endocrine; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sparsentan
Endothelin receptor ET-A antagonist; Type-1 angiotensin II receptor antagonist
EDNRA, AGTR1Phase 4Proteinuria; Immunoglobulin A Nephropathy; Focal Segmental Glomerulosclerosis; ANCA Associated VasculitisMar 2027
Pegtibatinase
PEG-modified cystathionine beta-synthase (CBS) enzyme replacement
CBSPhase 3HomocystinuriaJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03762850SparsentanPhase 3Immunoglobulin A NephropathyGenitourinaryAug 2023
NCT05003986SparsentanPhase 2Focal Segmental GlomerulosclerosisGenitourinaryMar 2027
NCT07219121SparsentanPhase 4ProteinuriaGenitourinaryMar 2027
NCT03406611PegtibatinasePhase 1HomocystinuriaMetabolic and endocrineJul 2027
NCT06247085PegtibatinasePhase 3HomocystinuriaMetabolic and endocrineAug 2027
NCT05630612SparsentanPhase 2ANCA Associated VasculitisCardiovascularSep 2027
NCT04663204SparsentanPhase 2Immunoglobulin A NephropathyGenitourinaryDec 2027

From the company's SEC filings

Cash and short-term investments of $303m on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

EDNRA (1) AGTR1 (1) CBS (1)

Companies with the same targets

Novartis AstraZeneca Noorik Biopharmaceuticals Johnson & Johnson (Janssen) THPharm HB BioTech Chong Kun Dang Pharmaceutical Yuhan Shenzhen Salubris Pharmaceuticals Shin Poong Pharmaceutical

Companies built like this

Lexicon Pharmaceuticals RECORDATI GROUP Medicure Crystalys Therapeutics Kailera

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.